Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension.

Authors

Arun Jose, George Washington University
Hind Rafei, George Washington University
Jalil Ahari, George Washington University

Document Type

Journal Article

Publication Date

10-1-2017

Journal

Pulmonary Circulation

Volume

7

Issue

4

Inclusive Pages

803-807

DOI

10.1177/2045893217716659

Abstract

Dasatinib is a small-molecule tyrosine kinase inhibitor used in the treatment of hematological malignancies. Pulmonary arterial hypertension (PAH) is a rare but known complication. The mainstay of treatment is cessation of Dasatinib, and while clinical improvement is rapid, complete hemodynamic resolution of pulmonary hypertension (PH) still remains exceedingly uncommon. We present a case of Dasatinib-induced PAH in a woman with chronic myeloid leukemia, who demonstrated rapid and complete clinical and hemodynamic resolution following treatment with combination pulmonary vasodilator therapy using an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. This case suggests there may be an association between the use of targeted PH medication in combination and the complete resolution of dasatinib-associated PAH, but further investigation is required.

Comments

Reproduced with permission of Sage Publishing. Pulmonary Circulation

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

APA Citation

Jose, A., Rafei, H., & Ahari, J. (2017). Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension.. Pulmonary Circulation, 7 (4). http://dx.doi.org/10.1177/2045893217716659

Peer Reviewed

1

Open Access

1